Tividenofusp alfa · Avlayah

Protein / enzyme therapeutic

Acceleratedapproval

Evidence outlook

Accelerated approval: Mucopolysaccharidosis Type II

Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (2)
Phase 1/2 (1)
Other / comorbidity

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Mucopolysaccharidosis Type II: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tividenofusp Alfa (Avlayah): this drugApprovedProtein / enzyme therapeuticIduronate-2-sulfatase (IDS)not yet gradedNo reviewed efficacy summary in this indication
Clemidsogene LanparvovecPhase 3Gene therapy / editingIduronate-2-sulfatase (IDS)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Avlayah (Tividenofusp alfa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
June 2027 (1)
Phase 2/3Mucopolysaccharidosis Type IIEnrolling by invitation
Est. primary completion 2027-06 · NCT06075537 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2/3Mucopolysaccharidosis Type IIActive not recruiting
Est. primary completion 2027-12 · NCT05371613 · CT.gov ↗
What to watch
2031 (1)
February 2031 (1)
Phase 1/2Mucopolysaccharidosis IIActive not recruiting
Est. primary completion 2031-02 · NCT04251026 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(6)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 April 2026FDA action dateFDA extends PDUFA date for tividenofusp alfa BLA to April 5, 2026
US, FDA · Source ↗
25 March 2026ApprovalFDA grants accelerated approval of AVLAYAH for Hunter syndrome
US, FDA · Source ↗
24 March 2026ApprovalFDA Boxed Warning on Avlayah (BLA761485)
US, FDA · FDA · Source ↗
7 July 2025Filing acceptedFDA accepts BLA for tividenofusp alfa
US, FDA · Source ↗
7 July 2025Priority reviewFDA grants Priority Review for tividenofusp alfa BLA
US, FDA · Source ↗
2 April 2025Filing submittedRolling BLA submission initiated for tividenofusp alfa
US, FDA · Source ↗